ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025
Symptomatic (STB) and Asymptomatic (ATB) tuberculosis in Italy: Results from a multicenter retrospective study.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Performance of Human and Computer-aided Evaluation of Digital Chest Radiography for Community-based Screening of Asymptomatic Tuberculosis.medRxiv : the preprint server for health sciences · 2026Article
- The hidden burden: a regional study revealing the substantial burden and distinct epidemiology of asymptomatic pulmonary tuberculosis in Southern China.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Asymptomatic tuberculosis (ATB) represents a significant proportion of tuberculosis (TB) cases. This study aimed to compare ATB and symptomatic TB (STB) cases in terms of demographic and clinical characteristics, adverse events, hospital length of stay, and treatment outcomes. Methods: This multicenter retrospective study included 510 microbiologically confirmed pulmonary TB patients across ten Italian hospitals between 2018 and 2023. STB cases presented with at least one symptom such as cough, fever, chest pain, hemoptysis, dyspnea, night sweats or weight loss. ATB cases presented with no symptoms. The endpoints included adverse events, length of hospital stay, and incompleteness of the treatment. Results: ATB accounted for 36.4 % of cases (184/510). STB was significantly associated with diabetes (p = 0.03), hepatitis B/C infections (p < 0.0001), and history of TB (p = 0.01). Adjusting for clinically relevant confounders, STB was associated with higher occurrence of adverse events (odds ratio 2.04, 95 % confidence interval 1.31 to 3.23; p = 0.002), more severe adverse events (odds ratio 8.07, 95 % confidence interval 2.58 to 33.34; p = 0.001) and a 24 % increase in length of hospital stay (95 % confidence interval 7 % to 47 %; p = 0.005), but was not associated with incomplete treatment (odds ratio 0.79, 95 % confidence interval 0.47 to 1.32; p = 0.37). Conclusions: STB is associated with a higher burden of adverse events. ATB poses challenges for TB elimination due to its asymptomatic nature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.